Scroll

tadalafil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
inhibitors of phosphodiesterase PDE5 with vasodilator action	2553	171596-29-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: zalutia tadalafil tardenafil tildenafil cialis IC351	A carboline derivative and PHOSPHODIESTERASE 5 INHIBITOR that is used primarily to treat ERECTILE DYSFUNCTION; BENIGN PROSTATIC HYPERPLASIA and PRIMARY PULMONARY HYPERTENSION. Molecular weight: 389.41 Formula: C22H19N3O4 CLOGP: 2.58 LIPINSKI: 0 HAC: 7 HDO: 1 TPSA: 74.87 ALOGS: -3.19 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

zalutia
tadalafil
tardenafil
tildenafil
cialis
IC351

A carboline derivative and PHOSPHODIESTERASE 5 INHIBITOR that is used primarily to treat ERECTILE DYSFUNCTION; BENIGN PROSTATIC HYPERPLASIA and PRIMARY PULMONARY HYPERTENSION.

Molecular weight: 389.41
Formula: C22H19N3O4
CLOGP: 2.58
LIPINSKI: 0
HAC: 7
HDO: 1
TPSA: 74.87
ALOGS: -3.19
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
10	mg	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	16 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.73 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Showing 1 to 3 of 3 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Nov. 21, 2003	FDA	LILLY

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dyspnoea	2029.28	15.65	3654	95568	657659	62732141
Pulmonary arterial hypertension	1801.17	15.65	821	98401	21756	63368044
Pain in jaw	1699.18	15.65	977	98245	42519	63347281
Fluid retention	1560.82	15.65	1038	98184	58648	63331152
Headache	1309.29	15.65	2975	96247	630266	62759534
Dyspnoea exertional	1053.10	15.65	821	98401	59481	63330319
Drug ineffective	971.95	15.65	225	98997	1044540	62345260
Right ventricular failure	943.35	15.65	484	98738	16704	63373096
Pulmonary hypertension	863.56	15.65	601	98621	36522	63353278
Hypervolaemia	795.16	15.65	516	98706	27897	63361903

Showing 1 to 10 of 473 entries

Previous1 2 3 4 5…48Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Headache	666.45	12.64	1104	49547	199531	34706749
Pulmonary arterial hypertension	548.10	12.64	263	50388	8476	34897804
Fluid retention	480.48	12.64	360	50291	26527	34879753
Pain in jaw	454.32	12.64	265	50386	12775	34893505
Dyspnoea	421.89	12.64	1347	49304	375435	34530845
Right ventricular failure	366.74	12.64	201	50450	8583	34897697
Pulmonary hypertension	276.98	12.64	235	50416	20689	34885591
Flushing	274.55	12.64	284	50367	32136	34874144
Dyspnoea exertional	229.72	12.64	298	50353	42981	34863299
Hypervolaemia	198.89	12.64	190	50461	19519	34886761

Showing 1 to 10 of 277 entries

Previous1 2 3 4 5…28Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dyspnoea	2004.60	12.25	4292	123557	852733	78763806
Pulmonary arterial hypertension	1998.17	12.25	954	126895	27412	79589127
Pain in jaw	1914.74	12.25	1088	126761	45063	79571476
Fluid retention	1818.30	12.25	1223	126626	68586	79547953
Headache	1665.07	12.25	3395	124454	650377	78966162
Right ventricular failure	1147.10	12.25	617	127232	22880	79593659
Dyspnoea exertional	966.22	12.25	925	126924	86148	79530391
Pulmonary hypertension	965.21	12.25	719	127130	47361	79569178
Hypervolaemia	867.16	12.25	643	127206	42047	79574492
Flushing	859.07	12.25	873	126976	87395	79529144

Showing 1 to 10 of 649 entries

Previous1 2 3 4 5…65Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	C02KX52	CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES OTHER ANTIHYPERTENSIVES Antihypertensives for pulmonary arterial hypertension
ATC	C02KX54	CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES OTHER ANTIHYPERTENSIVES Antihypertensives for pulmonary arterial hypertension
ATC	G04BE08	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Drugs used in erectile dysfunction
ATC	G04CA54	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY Alpha-adrenoreceptor antagonists
ATC	G04CB51	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY Testosterone-5-alpha reductase inhibitors
CHEBI has role	CHEBI:35620	vasodilator agents
CHEBI has role	CHEBI:71942	PDE5 inhibitor
FDA EPC	N0000175599	Phosphodiesterase 5 Inhibitor
FDA MoA	N0000020026	Phosphodiesterase 5 Inhibitors
MeSH PA	D002317	Cardiovascular Agents

Showing 1 to 10 of 15 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Pulmonary hypertension	indication	70995007	DOID:6432
Benign prostatic hyperplasia	indication	266569009
Impotence	indication	397803000
Induratio penis plastica	contraindication	1335005	DOID:8616
Priapism	contraindication	6273006	DOID:9286
Hearing loss	contraindication	15188001
Myocardial infarction	contraindication	22298006	DOID:5844
Alcohol intoxication	contraindication	25702006
Fibrosis of corpus cavernosum	contraindication	32608004
Low blood pressure	contraindication	45007003

Showing 1 to 10 of 31 entries

Previous1 2 3 4Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.3	acidic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
20MG/5ML	TADLIQ	CMP DEV LLC	N214522	June 17, 2022	RX	SUSPENSION	ORAL	11382917	Dec. 24, 2038	TADLIQ IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO IMPROVE EXERCISE ABILITY
20MG/5ML	TADLIQ	CMP DEV LLC	N214522	June 17, 2022	RX	SUSPENSION	ORAL	11666576	Dec. 24, 2038	TADLIQ IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO IMPROVE EXERCISE ABILITY

Showing 1 to 2 of 2 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
cGMP-specific 3',5'-cyclic phosphodiesterase	Enzyme	O76074	PDE5A_HUMAN	INHIBITOR	Ki	8	CHEMBL	CHEMBL
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A	Enzyme	Q9HCR9	PDE11_HUMAN		IC50	7.48	CHEMBL
Phosphodiesterase 6	Enzyme	O43924 P16499 P18545 P35913 P51160 Q13956	PDE6D_HUMAN PDE6A_HUMAN CNRG_HUMAN PDE6B_HUMAN PDE6C_HUMAN CNCG_HUMAN		IC50	6.01	CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	4	CHEMBL
Nuclear receptor subfamily 2 group E member 1	Nuclear hormone receptor	Q9Y466	NR2E1_HUMAN		EC50	5.30	CHEMBL
Acetylcholinesterase	Enzyme		ACES_RAT		IC50	4.58	CHEMBL
cGMP-specific 3',5'-cyclic phosphodiesterase	Enzyme		PDE5A_RAT		Ki	8.30	CHEMBL
cGMP-specific 3',5'-cyclic phosphodiesterase	Enzyme		PDE5A_BOVIN		IC50	8.48	CHEMBL
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha	Enzyme		PDE6A_BOVIN		IC50	5.52	CHEMBL
Phosphodiesterase 6	Enzyme		CNRG_BOVIN PDE6A_BOVIN PDE6C_BOVIN CNCG_BOVIN PDE6B_BOVIN PDE6D_BOVIN		IC50	5.29	CHEMBL

Showing 1 to 10 of 10 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
CIA	PDB_CHEM_ID
009874	NDDF
110635	PUBCHEM_CID
17580	MMSL
245338	MMSL
303263	RXNORM
4021415	VUID
4021415	VANDF
407111005	SNOMEDCT_US
407734006	SNOMEDCT_US

Showing 1 to 10 of 22 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ALYQ	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3334	TABLET, FILM COATED	20 mg	ORAL	ANDA	27 sections
ALYQ	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3334	TABLET, FILM COATED	20 mg	ORAL	ANDA	27 sections
Cialis	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4462	TABLET, FILM COATED	5 mg	ORAL	NDA	34 sections
Cialis	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4462	TABLET, FILM COATED	5 mg	ORAL	NDA	34 sections
Cialis	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4462	TABLET, FILM COATED	5 mg	ORAL	NDA	34 sections
Cialis	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4463	TABLET, FILM COATED	10 mg	ORAL	NDA	34 sections
Cialis	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4463	TABLET, FILM COATED	10 mg	ORAL	NDA	34 sections
Cialis	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4463	TABLET, FILM COATED	10 mg	ORAL	NDA	34 sections
Cialis	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4464	TABLET, FILM COATED	20 mg	ORAL	NDA	34 sections
Cialis	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4464	TABLET, FILM COATED	20 mg	ORAL	NDA	34 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next